Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Iovance Biotherapeutics progresses on BLA for lifileucel, faces recruitment challenges

Iovance Biotherapeutics is on track with BLA completion expected this quarter, strong pipeline progress, and manufacturing capacity expansion. Challenges include study recruitment uncertainties and the ongoing CEO search. Opportunities exist in new program data releases, European expansion, and pivotal study enrollment.

Iovance Biotherapeutics advances TIL therapy pipeline with strong financials

Iovance Biotherapeutics is on track with key milestones in TIL therapy development and commercialization.
The company's financial position is stable, with strategic investments supporting future growth.
Challenges include operational efficiency, FDA interactions, and trial progress management.
Opportunities lie in international trials, market expansion, and revenue growth post-launch.

Iovance Biotherapeutics reports Q2 loss, eyes lifileucel FDA review

Iovance Biotherapeutics faces financial challenges with a significant net loss in Q2 2023, despite positive milestones and revenue from Proleukin sales.
The company's TIL therapy pipeline shows promise with progress in key clinical trials, while opportunities exist for market differentiation and revenue growth.
Challenges include ongoing financial losses, longer timelines for pivotal studies, and potential delays in trial enrollment, requiring strategic management.

Iovance Biotherapeutics progresses on Lifileucel commercialization and pipeline expansion

Iovance Biotherapeutics is making significant strides in advancing its pipeline and commercialization efforts, with a strong focus on FDA approval for Lifileucel and expanding into key markets. The company faces challenges in labeling discussions and efficacy benchmarks but has opportunities in European marketing, new therapy programs, and potential partnerships for international growth.

Iovance Biotherapeutics excels with Amtagvi approval and clinical progress

Iovance Biotherapeutics showcased strong performance with the FDA approval of Amtagvi and progress in clinical trials, positioning the company for growth.
While facing challenges in scaling operations and regulatory hurdles, the company's focus on efficiency and clinical research strengths bode well for the future.
With opportunities in label expansion, market penetration, and revenue growth, Iovance is poised to capitalize on its innovative therapies and drive value for stakeholders.

Iovance Biotherapeutics reports Q1 loss, Amtagvi launch success

Iovance Biotherapeutics shows promising performance with a focus on Amtagvi's commercial success and pipeline advancements.
Strengths include positive reimbursement trends, successful patient selection processes, and efficient manufacturing operations.
Challenges lie in patient screening failures, financial clearance issues, and variability in bridging therapy usage.
Opportunities for growth include market expansion, high patient conversion rates, and accelerated submission processes for new therapies.

Iovance Biotherapeutics (IOVA) exceeds Q3 revenue targets, eyes global expansion

Iovance Biotherapeutics (IOVA) had a strong Q3 performance, exceeding revenue guidance and showcasing growth potential.
The company's focus on Amtagvi and global expansion presents opportunities for revenue diversification and market penetration.
Challenges lie in maintaining adoption rates, meeting revenue targets, and effectively managing increased manufacturing capacity.
Overall, IOVA's strategic initiatives position it for continued growth and success in the biopharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN CARLOS, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conference:

Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

Whenever your stock tumbles due to a temporary issue, it will nearly always rebound at resolution in the ensuing months. Iovance Biotherapeutics' potency assay for lifileucel caused a huge haircut in the share price.

Iovance: Onward To Approval

Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later this year.

Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why

Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.

Iovance (IOVA) to Seek FDA Nod for Melanoma Therapy in August

Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma

Iovance Biotherapeutics focuses on developing treatments for cancers, a market with minimal supply and large demand. The company recently received approval to proceed with further investigations into a revolutionary new treatment for NSCLCs. The company relies on smart partnerships for research and development to avoid accruing excess debt. Iovance has no viable products on the market to date, which means they generate no revenue or profit, which adds significant risk to investment.

Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside

Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.

Iovance (IOVA) to Start Clinical Studies for TIL Therapy

Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001  to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy

Iovance Biotherapeutics' Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)

SAN CARLOS, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the acceptance of two abstracts for presentation at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting April 8-13, 2022 in New Orleans, Louisiana and virtual. Details for the abstracts are as follows:

Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting

Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.

Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss

Iovance Biotherapeutics' (IOVA) CEO Fred Vogt on Q4 2021 Results - Earnings Call Transcript

Expanding TIL Platform in Multiple Solid Tumors and Treatment Settings Expanding TIL Platform in Multiple Solid Tumors and Treatment Settings

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates

SAN CARLOS, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year financial results on Thursday, February 24, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022

Bilibili

iQIYI

Invitae

Peloton

TG Therapeutics

Tencent Music Entertainment Group 

Bargain-hunting investors have good reason to be tempted, but a steep sell-off alone isn't enough of a bullish argument.

Are These 7 of the Worst-Performing Stocks of 2021 Ready to Skyrocket This Year?

SAN CARLOS, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Raj K. Puri, M.D., Ph.D., will join the Company as Executive Vice President, Regulatory Strategy and Translational Medicine. Dr. Puri will begin his employment with the Company toward the end of the first quarter of 2022.

Iovance Biotherapeutics Announces Raj K. Puri, M.D.

TIL Therapy was Successfully and Consistently Manufactured from Cryopreserved Tumor Samples Shipped from Australia

Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Fred Vogt, PhD, Esq., Interim Chief Executive Officer, President and General Counsel of Iovance, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30 a.m. ET. The live and archived webcasts of the presentation will be available in the Investors section of the Iovance website at http://ir.iovance.com.

Iovance Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced data for lifileucel in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients with advanced cancers. Data were presented at the Society for Immunotherapy of Cancer Annual Meeting.

Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers

The stock price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) increased by over 4% pre-market today. This is why it happened.

Iovance Biotherapeutics (IOVA) Stock: Why The Price Increased Today

Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients Shows Overall Response Rate (ORR) of 57% in Cervical Cancer, 60% in Melanoma with 30% Complete Response (CR) and 39% in Head and Neck Cancer

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced additional data for LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) enrolled in Cohort 3B of the basket study IOV-COM-202.  The results demonstrate the feasibility of LN-145, a tumor-infiltrating lymphocyte TIL cell therapy in heavily pre-treated patients.

Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial

21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC)

Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting

TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naïve Cervical Cancer, Melanoma, and Head and Neck Cancer

Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics' (IOVA) third-quarter loss is wider than expected. The company is progressing well in terms of development of pipeline candidates.

Iovance (IOVA) Reports Wider-Than-Anticipated Loss in Q3

Iovance Biotherapeutics' (IOVA) CEO Fred Vogt on Q3 2021 Results - Earnings Call Transcript

News for Iovance Biotherapeutics Stock (IOVA)